Press Release: Fortinet, Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Fortinet, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Fortinet, Inc. (“Fortinet” or the “Company”) (NASDAQ:FTNT) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at This email address is being protected from spambots. You need JavaScript enabled to view it., or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit…
LOS ANGELES, March 12, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pomdoctor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pomdoctor between October 9, 2025 and December 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson…
Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Smart Materials Market, Till 2035: Distribution by Type of Material, Type of Application, Type of End User, Geographical Regions: Industry Trends and Global Forecasts" report has been added to ResearchAndMarkets.com's offering.
Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG. As of 09 March 2026, UBS Group AG held a total of 7,370,166 shares and voting rights in Bang & Olufsen A/S, corresponding to 5.00 percent of the total share capital and voting rights.
CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) -- New research from the American Medical Association’s Center for Digital Health and AI shows that physicians’ adoption of augmented intelligence (AI) continues to grow as confidence builds in the technology’s clinical advantages.
